Supervisory Board

Colin Michael Bond who was born on January 26, 1960 in Upminster, United Kingdom, holds a Bachelor of Science degree in pharmacy and a master’s degree in business administration from London Business School. During his early career, Colin Michael Bond worked as auditor and management consultant for PricewaterhouseCoopers, Arthur Andersen and Procter & Gamble. From 2010 to 2016, he served as Chief Financial Officer (CFO) of Evotec SE, which is listed on the Frankfurt Stock Exchange (Prime Standard) as well as NASDAQ. From 2016 to 2022, Colin Michael Bond served as Chief Financial Officer (CFO) of Vifor Pharma Management AG. From 2022 to June 2024, he served as Chief Financial Officer (CFO) of Sandoz AG. Colin Michael Bond is a Fellow of the Institute of Chartered Accountants in England and Wales, and a member of the Royal Pharmaceutical Society of Great Britain.

Alongside his office as a member of the Supervisory Board, Colin Michael Bond is, or was within the last five years, a member of the administrative, management or supervisory bodies of and/or a partner in the following companies and partnerships:

Currently:

• BioPharma Credit Plc, Leeds, United Kingdom, member of the board of directors.
• Agomab Therapeutics NV, Antwerp, Belgium, member of the board of directors
• Oxford Biomedica PLC, Oxford, United Kingdom, member of the board of directors (as of January 1, 2025)

Previously:

• Sandoz AG, Basel, Switzerland, member of the board of directors (from 2022 to 2024);
• Siegfried Holding AG, Zofingen, Switzerland, member of the board of directors (from 2013 to 2023); and
• Vifor Pharma Management AG, Glattbrugg, Switzerland, member of the board of directors (from 2016 to 2022).

Other than listed above, Colin Michael Bond is not, and was not within the last five years, a member of any administrative, management or supervisory body of and/or a partner in any other company or partnership.

Nicholas Haggar who was born on April 25, 1965 in Norwich, United Kingdom, has over thirty years of experience in building pharmaceutical businesses. With an Master of Business Administration from Cranfield School of Management and a Bachelors Degree in Industrial and Manufacturing Systems Engineering, Nicholas Haggar began his professional career in pharmaceutical technical operations before moving into commercial and enterprise leadership. Nicholas serves on the Zentiva board since 2023, having been Chief Executive Officer of Zentiva following its carve-out from Sanofi in 2018. Nicholas Haggar has been active in the biosimilar space for the last 15 years. Currently, he serves as Chief Executive of HealthQube Ltd., a UK-based investment, analytics and consultancy platform.

Alongside his office as a member of the Supervisory Board, Nicholas Haggar is, or was within the last five years, a member of the administrative, management or supervisory bodies of and/or a partner in the following companies and partnerships outside Formycon:

Currently:

• Zentiva K.S. International, Prague, Czech Republic, non-executive director;
• Biocon Limited, Bangalore, India, independent director;
• Biocon Biologics Ltd., Bangalore, India, independent director;
• Biocon Biologics UK Ltd., London, United Kingdom, non-executive director;
• Biosimilars NewCo Ltd., London, United Kingdom, non-executive director;
• Biosimilars Collaborations Ireland Ltd., Dublin, Ireland, non-executive director;
• Healthqube Ltd, Chalfont St. Giles, United Kingdom, chief executive officer; and
• Polpharma Generic BV, non-executive chairman.

Previously:

• Zentiva K.S., Prague, Czech Republic, chief executive officer (from 2019 to 2023).

Other than listed above, Nicholas Haggar is not, and was not within the last five years, a member of any administrative, management or supervisory body of and/or a partner in any other company or partnership outside Formycon.

Klaus Röhrig, who was born on July 21, 1977 in Vienna, Austria, studied business administration at the Vienna University of Economics and Business. He holds a Master of Economics and Business Administration from Vienna University of Economics and Business Administration. In 2000, he started his career at Credit Suisse First Boston in London, United Kingdom, focusing on corporate finance and M&A for technology companies. From 2002 to 2006, he worked for Mercury Capital GmbH in Vienna, Austria. In 2006, he joined Elliott Associates in London, United Kingdom, where he worked until 2012 and was responsible for the funds’ investments in the German speaking countries. Since 2015, he is founding partner and Co-Chief Investment Officer of Active Ownership Capital S.à r.l., an independent, partner-managed investment firm operating primarily in Continental Europe and Scandinavia.

Alongside his office as a member of the Supervisory Board, Klaus Röhrig is, or was within the last five years, a member of the administrative, management or supervisory bodies of and/or a partner in the following companies and partnerships outside Formycon:

Currently:

• Agfa-Gevaert N.V., Belgium, member of board of directors (non-executive director);
• Fagron NV, Belgium, member of board of directors (non-executive director);
• Francotyp-Postalia Holding AG, deputy chairman of the supervisory board;
• R3 Capital GmbH, Vienna, Austria, managing director;
• R3ND Immobilien GmbH, Vienna, Austria, managing director;
• Mercury Capital GmbH, Vienna, Austria, managing director;
• MAM Baby AG, Wollerau, Switzerland, member of the board of directors;
• Active Ownership Corporation S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
• Active Ownership Capital S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
• White Elephant Holdco S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
• White Elephant S.à. r.l., Grevenmacher, Luxembourg,, member of the management board;
• AOC Technology SAS, Grevenmacher, Luxembourg, member of the management board;
• AOC Value SAS, Grevenmacher, Luxembourg, member of the management board;
• H2APEX Management S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
• AOC Health Holdco S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
• AO Gaming S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
• AOC Cloud S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
• Aonic Holdco S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
• Aonic Holdco 2 S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
• Aonic Midco S.à. r.l., Grevenmacher, Luxembourg, member of the management board
• AO MLP S.à. r.l., Grevenmacher, Luxembourg, member of the management board; and
• AOC Pharma S.à. r.l., Grevenmacher, Luxembourg, member of the management board.

Previously: none

Other than listed above, Klaus Röhrig is not, and was not within the last five years, a member of any administrative, management or supervisory body of and/or a partner in any other company or partnership outside Formycon.

Dr. Bodo Coldewey, who was born on December 16, 1971 in Oldenburg, Germany, completed his studies in business engineering at the Technical University of Kaiserslautern and his doctorate at the Leipzig Graduate School of Management. In 1997, he began his professional career as consultant at KPMG Deutschland, where he worked until June 2000. In July 2000, he joined 3i Group plc as investment manager, where he worked until September 2002. From October 2002 to December 2011, Dr. Bodo Coldewey served as director of Oldenburgische Landesbank AG. Since 2012, he is managing director of the family office WEGA Invest GmbH.

Alongside his office as a member of the Supervisory Board, Dr. Bodo Coldewey is, or was within the last five years, a member of the administrative, management or supervisory bodies of and/or a partner in the following companies and partnerships outside Formycon:

Currently:

• WEGA Support GmbH, managing director;
• WEGA Invest GmbH, managing director;
• WEGA Beteiligungsverwaltungsgesellschaft mbH, managing director;
• Dozena GmbH, managing director;
• PW Garrel Verwaltungs GmbH, managing director;
• BW Garrel Verwaltungs GmbH, managing director; and
• WEGA EQUITY AUDA Beteiligungs-GmbH i.L., managing director and liquidator.

Previously: None

Other than listed above, Dr. Bodo Coldewey is not, and was not within the last five years, a member of any administrative, management or supervisory body of and/or a partner in any other company or partnership outside Formycon.